AMS / H.B. Fuller: Adding on the Extended Bid

Advanced Medical Solutions (AMS), the AIM-listed tissue-healing specialist, remains in a live offer period. On 18 June the board confirmed that talks with H.B. Fuller over a possible all-cash takeover are ongoing, and the “put up or shut up” deadline has been just extended to 2 July. An extension isn’t a firm offer — but choosing it over a walk-away keeps the deal alive, and the Takeover Panel only consents when negotiations are genuinely progressing.

The strategic logic is sound: H.B. Fuller, an industrial-adhesives group, is pushing into healthcare, and AMS’s tissue-adhesive technology is a clean fit.

What draws me in is the price. The reported offer is around 285p — a 30%-plus premium to the undisturbed level near 210p. With the shares at 222p, the market implies only modest odds of completion:

Implied probability ≈ (price − floor) ÷ (offer − floor)
                    = (222 − 210) ÷ (285 − 210)
                    = 12 ÷ 75 ≈ 16%

Roughly a one-in-six shot — too pessimistic, I think, for a live, advised process. The asymmetry is the appeal: ~28% upside to 285p against modest downside if it lapses (the shares would likely drift back toward the low 200s, not collapse).

On that basis, I’m increasing my position. The main risk is Fuller walking under activist pressure — but at these odds, I’ll take it.

Not investment advice.